Developer docs
API playgroundTry for free, no card

Search company profiles

Invaio Sciences

Full company profile

uuid0002akl

Namestring
Invaio Sciences
Legal namestring
Invaio Sciences, Inc.
Websiteurl
invaio.com
Company typeenum
Private
Founded yearint
2018
Descriptiontext

Invaio Sciences is a privately held agricultural biotechnology company founded in 2018 by Flagship Pioneering and headquartered in Cambridge, Massachusetts, with operations across six offices in the US, Brazil, Spain, Switzerland, and Italy. The company develops nature-positive crop protection technologies built around an AI-driven peptide discovery engine (Biologicals by Design™) and three proprietary delivery platforms — Trecise™ precision vascular infusion for trees, Microbe-Derived Particles (MDPs), and Nature-derived Lipid nanoParticles (NLPs) — that together are positioned as a vertically integrated stack for designing, protecting, and delivering bioactives into plants. Its commercial focus is anchored on citrus greening (HLB), where it obtained the first-ever regulatory registration for a Trecise™-based HLB solution in August 2023, and on adjacent opportunities in vegetables (e.g., diamondback moth) and row crops (e.g., corn rootworm); the December 2023 acquisition of Peptyde Bio added a defensin-based antimicrobial peptide pipeline.

Invaio pursues an enterprise B2B go-to-market that targets global agribusinesses and supply-chain leaders rather than individual growers, with named partners including Fundecitrus, Louis Dreyfus Company, and The Coca-Cola Company ("Save the Orange" initiative). Revenue mechanics are not publicly disclosed, but the model blends negotiated multi-year contracts routed through regional specialist sales teams with strategic co-development partnerships, future manufacturing collaborations (most notably with Ginkgo Bioworks for fermentation scale-up, announced February 2026), and downstream licensing potential. The company has raised over $142 million since inception — including an $88.9 million Series C led by Flagship Pioneering in May 2021 and $50 million in debt financing from K2 HealthVentures in October 2021 — and currently employs around 90 people of 22 nationalities.

The business is led by CEO and Board Director Amy O'Shea (appointed April 2024), with a leadership team that includes President/CCO Peleg Chevion, CCO Chris Judd, CFO Scott Kantor, and CSO Magalie Guilhabert, supported by a Scientific Advisory Board chaired by HHMI/NAS investigator Steve Jacobsen and including Nobel laureate Randy Schekman. Board representation spans PepsiCo (Pietro Tataranni), Ginkgo Bioworks (Ena Cratsenburg), and Novartis AI (Iya Khalil), providing direct cross-sector leverage into nutrition, synthetic biology, and AI/ML commercialization channels that complement the company's enterprise distribution strategy.

Short descriptiontext

Invaio Sciences is an agricultural biotechnology company that uses an AI-driven peptide discovery engine and proprietary delivery platforms (Trecise™, MDPs, NLPs) to develop nature-positive crop protection solutions for citrus, vegetable, and row crop growers, sold via enterprise partnerships with global agribusinesses and supply-chain leaders.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
51–100
akta.pro rankint
HeadquartersCambridge, United States
HQ citystring
Cambridge
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Offices7 records

Each record includes

City, Country, Type, Description, Source

Keyword5 values
biological crop protection, agricultural biotechnology, peptide discovery, precision delivery, sustainable agriculture
Industry3 codes
PRIMARYAFABAEAN
Biologicals Distribution & Field Application Services
Agriculture & Food Production/Agricultural Inputs & Agrochemicals/Biologicals & Biopesticides (Microbials, Botanicals, Beneficial Insects)
SECONDARYAFABAEAL
Biological Seed Treatments & Inoculants (within Biologicals)
Agriculture & Food Production/Agricultural Inputs & Agrochemicals/Biologicals & Biopesticides (Microbials, Botanicals, Beneficial Insects)
SECONDARYAFABAKAL
Organic Adjuvants & Spray Aids (OMRI Surfactants, Stickers, Oils)
Agriculture & Food Production/Agricultural Inputs & Agrochemicals/Organic & Regenerative Inputs (OMRI Inputs, Compost, Natural Pest Control)
NAICS code3 codes
  • Pesticide, Fertilizer, and Other Agricultural Chemical Manufacturing3253
  • Pesticide and Other Agricultural Chemical Manufacturing32532
  • Pesticide and Other Agricultural Chemical Manufacturing325320
SIC code2 codes
  • Agricultural Chemicals2870
  • Biological Products, (No Disgnostic Substances)2836
Product category
Agricultural biotechnology — biological crop protection
Social media profiles3 records
GTM motion4 records

Each record includes

Type, Description, Source

Revenue model3 records
1Commercial product sales (pre-launch / transition phase)
TypeHardware Sales
Description

Series C press release (May 25, 2021) explicitly states Invaio is using funds 'to expand its sustainable agriculture technology platforms' and 'transition from R&D to a fully commercial enterprise focused on eco-friendly farming methods,' indicating product sales to growers and agribusiness customers are the intended primary revenue model as Invaio Citrus Health™ and Trecise™-based products launch. No specific pricing or revenue figures are disclosed.

invaio.com
2Strategic co-development and partnership-derived revenue
TypeProfessional Services
Description

Revenue is also generated via strategic partnerships where Invaio supplies its Trecise™ / Biologicals by Design™ platforms to partners (e.g., Fundecitrus, Louis Dreyfus, The Coca-Cola Company, Ginkgo Bioworks) for joint development of HLB and crop protection solutions; the company describes preparing 'to launch our first HLB solution in Brazil.'

invaio.com
3Future licensing / manufacturing collaboration (with Ginkgo Bioworks)
TypeLicensing Royalties
Description

The February 2026 collaboration with Ginkgo Bioworks covers microbial strain engineering and fermentation scale-up for Invaio's peptide-based crop protection inputs, positioning Invaio for grower-friendly commercial-scale production and downstream licensing/royalty potential.

stocktitan.net
Marketing channels9 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels4 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components6 values
Personnel, Technology or R&D, Operations, Marketing or Sales, Supply Chain, Infrastructure
Pricing details1 tier
1Quote-based B2B enterprise pricing — not publicly disclosed
ModelOtherBilling cadenceMulti-year contract
Notes

No public price list, tier or subscription model is published. Sales is routed through Invaio specialist teams in Cambridge (HQ), RTP, Florida, Brazil, Italy, Spain and Switzerland. Invaio describes itself as a partner rather than a self-serve vendor.

invaio.com
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Brand1 of 3 records shown
1Biologicals by Design™
Description

Proprietary AI- and machine-learning-powered discovery platform for designing nature-informed peptides for crop protection.

invaio.com
+2 more records
Core offering1 text field

Invaio Sciences develops and sells biological crop-protection solutions built on an AI-driven antimicrobial peptide discovery engine (Biologicals by Design™) paired with proprietary precision delivery platforms (Trecise™ tree infusion, Microbe-Derived Particles and Nature-derived Lipid nanoParticles). Its packaged solution lines target citrus greening (HLB) via Invaio Citrus Health™, vegetable pests and row-crop insects, and are sold primarily through enterprise partnerships with global agribusinesses and supply-chain leaders rather than direct-to-grower retail.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 4 values shown
  • Biologicals by Design™ platform is 10x more efficient than traditional chemical discovery methods at identifying novel crop health solutions
+3 more records
Product overview1 text field

Invaio Sciences offers a platform-plus-modules architecture for nature-positive agriculture. The core engine is the Biologicals by Design™ AI-driven peptide discovery platform, which is paired with three proprietary delivery platforms — Trecise™ (precision tree infusion), Nature-derived Lipid nanoParticles (NLPs), and Microbe-Derived Particles (MDPs) — that protect and deliver bioactives into crops. These platforms are packaged into solution lines targeting Tree Health (including Invaio Citrus Health™ for HLB/citrus greening), Vegetable Health, and Row Crop Health, with the Peptyde Bio antimicrobial peptide portfolio integrated after the December 2023 acquisition to bolster the fungicide and broader peptide pipeline.

Product and service7 records
1Invaio Citrus Health™
CategorySolution line — Citrus crop protection
Description

Invaio's first citrus-focused solution targeting Huanglongbing (HLB/citrus greening); combines Trecise™ precision tree-infusion delivery with peptide-based bioactives and is suitable for use even on young trees. Targeted at Florida and Brazilian citrus growers.

2Tree Health Solutions
CategorySolution line — Tree crop protection
Description

Solution line covering perennial crop trees (including citrus and other tree crops) using Trecise™ delivery to protect tree health from pests and disease while reducing pesticide, water and nutrient inputs.

3Vegetable Health Solutions
CategorySolution line — Vegetable crop protection
Description

Targeted bioactives and delivery systems aimed at controlling pests in vegetable crops, including MDP-encapsulated peptides and proteins targeting diamondback moth and other resistant insect pests; demonstrated 2–5× performance vs. commercial biological benchmark in cabbage, kale, broccoli and cauliflower trials.

4Row Crop Health Solutions
CategorySolution line — Row crop protection
Description

Approaches for row crops including corn rootworm control, leveraging peptide and RNA-based actives delivered via MDP and NLP platforms to address insecticide-resistant populations in corn and other row crops.

5Biologicals by Design™ platform
CategoryDiscovery platform — AI/ML peptide design
Description

AI-driven peptide discovery and design platform that uses generative AI, deep machine learning, structure-guided design, and genome mining for antimicrobial peptides to generate programmable, nature-derived active ingredients targeting specific pests and diseases with novel modes of action. Reported as 10x more efficient than traditional chemical discovery methods at identifying novel crop-health solutions. Sold/licensed to enterprise partners as part of co-development engagements.

6Trecise™ precision infusion delivery system
CategoryDelivery platform — Precision tree infusion
Description

Proprietary precision infusion/tree-injection delivery technology that places active ingredients directly into the vascular system of trees, dramatically reducing chemical spray needs. Deployed commercially as the delivery backbone for Invaio Citrus Health™ against HLB and described as the first major innovation around targeted delivery in crop protection in 25 years.

7Peptyde Bio antimicrobial peptide platform (acquired pipeline)
CategoryAcquired pipeline — Antimicrobial peptide discovery
Description

Antimicrobial peptide discovery, design and characterization platform acquired by Invaio from Peptyde Bio in December 2023. Brings peptide candidates that complement or replace traditional chemical fungicides and integrates with Invaio's Biologicals by Design™ platform; focused initially on defensin-class AMPs for Botrytis cinerea, Fusarium spp., Septoria blotch, Asian soybean rust and certain oomycetes.

Scale indicator12 records

Each record includes

Type, Value, Description, Source

Partnership11 partners
Strategic tierFlagshipTypeTechnology or IntegrationAnnounced on2026-02-18
Description

Collaboration announced February 18, 2026, in which Ginkgo Bioworks and Invaio Sciences will develop manufacturing technology for peptide-based crop protection products. Ginkgo will leverage its engineered microbial strains and fermentation processes to help Invaio scale production of peptides at grower-friendly costs, addressing increasing pest resistance to conventional agricultural chemistry.

Strategic tierFlagshipTypeStrategic or Co-development PartnerAnnounced on2026-01-13
Description

Strategic collaboration announced January 13, 2025 (press release dated Jan 13, 2026) between Invaio Sciences and Fundecitrus (Fund for Citrus Protection, Araraquara, Brazil) to accelerate evaluation of peptide-based biological solutions against citrus greening (HLB). Fundecitrus provides specialized assays and field-based methods because CLas cannot be cultured in vitro; Invaio deploys its Trecise™ precision delivery platform to test candidates directly into citrus trees. Quotes from Ricardo Miranda (VP, Head of Global Development) and Avram Slovic (Head of LatAm).

Strategic tierFlagshipTypeGTM or Marketing PartnerAnnounced on2025-09-05
Description

Press release dated September 5, 2025: 'Invaio Sciences Joins Forces with The Coca-Cola Company to Save the Orange.' Invaio participates in the Save the Orange initiative with Coca-Cola and Fundecitrus, supporting the citrus supply chain's adoption of biological HLB solutions and bringing nature-positive crop protection to global beverage supply.

Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2024-01-29
Description

Press release dated January 29, 2024: 'Invaio Sciences and Louis Dreyfus Company Collaborate on Sustainable Citrus Groves for the Future.' The collaboration brings together Invaio's biological technologies and Louis Dreyfus' position as a major player in the global citrus supply chain to advance sustainable citrus production.

Strategic tierFlagshipTypeStrategic or Co-development PartnerAnnounced on2023-12-07
Description

On December 7, 2023, Invaio Sciences acquired Peptyde Bio, a company specializing in antimicrobial peptide technology for agriculture. The acquisition integrates Peptyde's portfolio of peptide candidates (defensins targeting Botrytis cinerea, Fusarium spp., Septoria blotch, Asian soybean rust, certain oomycetes) into Invaio's AI-driven Biologicals by Design™ discovery platform, accelerating sustainable crop protection solutions. The deal is believed to be the first exit for a Danforth Technology Company.

Strategic tierFlagshipTypeOthersAnnounced on2021-02-03
Description

Dr. Steve Jacobsen, Professor of Molecular Cell and Developmental Biology and Biological Chemistry at UCLA and Howard Hughes Medical Institute Investigator (elected to NAS in 2011), chairs Invaio's Scientific Advisory Board. He contributed to building the SAB and recruiting R&D talent, and is also a scientific co-founder of Inari Agriculture (a Flagship Pioneering company).

Strategic tierCoreTypeOthersAnnounced on2021-02-03
Description

Dr. Randy Schekman, Professor in the Department of Molecular and Cell Biology at the University of California, Berkeley, and HHMI investigator, joined the Invaio SAB. Schekman received the 2013 Nobel Prize in Medicine or Physiology for vesicle trafficking and joined to develop insights into harnessing vesicles to deliver biological molecules to plants.

Strategic tierCoreTypeOthersAnnounced on2021-02-03
Description

Dr. Rodolphe Barrangou, Distinguished Professor at NC State University (NAS, NAE, NAI and American Academy of Microbiology), joined the Invaio SAB. He brings experience commercializing CRISPR-related technologies and phage-host interaction science.

Strategic tierMinorTypeStrategic or Co-development PartnerAnnounced on2020-11-18
Description

On November 18, 2020, Invaio announced the appointment of Dr. Pietro Antonio Tataranni (Chief Medical Officer and Senior VP, R&D Life Sciences at PepsiCo) to its Board of Directors to contribute nutrition and bio-sciences expertise to Invaio's mission. PepsiCo itself is a board-affiliation partner rather than an operating commercial partner.

Strategic tierMinorTypeStrategic or Co-development PartnerAnnounced on2020-11-18
Description

Ena Cratsenburg, Chief Business Officer at Ginkgo Bioworks, joined Invaio's Board of Directors on November 18, 2020. This board relationship predated and supported the Feb 2026 manufacturing collaboration; Cratsenburg brings synthetic-biology and commercialization expertise.

Strategic tierMinorTypeStrategic or Co-development PartnerAnnounced on2020-11-18
Description

Dr. Iya Khalil, Global Head of the AI Innovation Center at Novartis (Novartis-Microsoft collaboration), joined Invaio's Board of Directors on November 18, 2020. Khalil is a co-founder of GNS Healthcare and brings AI / machine-learning expertise to support Invaio's discovery platforms.

Recent move6 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight6 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

Fellow Flagship Pioneering ag-biotech company developing microbial seed treatments and plant microbiome solutions. Directly comparable as a privately held, biology-based crop-inputs company backed by the same VC and pursuing nature-positive replacements for synthetic chemistries — Indigo also shares board overlap (Robert Berendes is Chairman of both Indigo and Invaio).

TypeDirect peer
Description

Flagship Pioneering ag-biotech applying predictive design and multiplex gene editing to seeds; co-founded by Ignacio Martinez (Invaio's founding CEO) with Steve Jacobsen (Invaio SAB Chair) as scientific co-founder. Closest Flagship-sibling competitor in applying computational biology to plant/crop inputs.

TypeDirect peer
Description

Ag-biotech company using a proprietary microbial GENESIS™ discovery platform to identify biological crop-protection products (e.g., Howler and Theia fungicides). Closely comparable technology stack (biology discovery platform → commercial biocontrol products) targeting the same growers and same chemical-replacement thesis.

TypeDirect peer
Description

Microbial nitrogen-fixation company selling in-furrow and foliar biological products to row-crop growers as a replacement for synthetic nitrogen fertilizer. Same broad thesis (microbes replace synthetic chemistry), same customer type (large-scale growers), and similar scale-up-from-R&D-to-commercial trajectory.

TypeEmerging player
Description

Ag-biotech developing microbial consortia products for nitrogen fixation, phosphorus solubilization, and biocontrol. Comparable discovery-then-product model and row-crop/specialty-crop overlap, though smaller and earlier-stage than Invaio.

TypeOthers
Description

Synthetic biology platform / cell-programming company that is also Invaio's manufacturing partner (Feb 2026 collaboration) and has a board representative (Ena Cratsenburg) on Invaio's board. Comparable in AI-driven biological design and biological manufacturing, but serves many end-markets beyond agriculture.

TypeEmerging player
Description

Ag-biotech offering microbe-based SOURCE™ nitrogen-fixation and EFFICIENCY™ bio-inspired chemistry products to row-crop growers. Comparable in offering nature-positive biological crop inputs that reduce synthetic fertilizer use; smaller scale and narrower product set than Invaio.

TypeBroad incumbent
Description

Global crop-protection incumbent (now part of Syngenta Group / Sinochem) offering chemical pesticides, seeds, and digital agronomy. Provides the synthetic chemistry baseline that Invaio's biologicals aim to replace; relevant as the dominant competitor Invaio must displace in growers' spray regimes.

TypeBroad incumbent
Description

Division of Bayer operating one of the world's largest crop-protection and seed franchises, with growing investment in biologics. Sets the competitive context for any nature-positive crop input alternative and is a benchmark for distribution scale.

10Corteva Agriscience
TypeBroad incumbent
Description

Global crop-protection and seed major spun out of DowDuPont; offers chemical and biological inputs across row and specialty crops. Comparable broad incumbent that biologicals companies like Invaio must compete against on grower relationships and shelf-space.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat5 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers4 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment4 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile3 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI capability8 records

Each record includes

Type, Description, Source

AI maturity
App detail

Has app

Feature6 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles19 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

Subsidiaries5 records

Each record includes

Name, Acquired on, Relationship type, Type, Business focus

Compliance3 records

Each record includes

Name, Class, Description

Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds4 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors6 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A1 record

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Invaio Sciences

Agricultural biotechnology — biological crop protectioninvaio.com

Invaio Sciences is an agricultural biotechnology company that uses an AI-driven peptide discovery engine and proprietary delivery platforms (Trecise™, MDPs, NLPs) to develop nature-positive crop protection solutions for citrus, vegetable, and row crop growers, sold via enterprise partnerships with global agribusinesses and supply-chain leaders.

What Invaio Sciences does

Invaio Sciences is a privately held agricultural biotechnology company founded in 2018 by Flagship Pioneering and headquartered in Cambridge, Massachusetts, with operations across six offices in the US, Brazil, Spain, Switzerland, and Italy. The company develops nature-positive crop protection technologies built around an AI-driven peptide discovery engine (Biologicals by Design™) and three proprietary delivery platforms — Trecise™ precision vascular infusion for trees, Microbe-Derived Particles (MDPs), and Nature-derived Lipid nanoParticles (NLPs) — that together are positioned as a vertically integrated stack for designing, protecting, and delivering bioactives into plants. Its commercial focus is anchored on citrus greening (HLB), where it obtained the first-ever regulatory registration for a Trecise™-based HLB solution in August 2023, and on adjacent opportunities in vegetables (e.g., diamondback moth) and row crops (e.g., corn rootworm); the December 2023 acquisition of Peptyde Bio added a defensin-based antimicrobial peptide pipeline.

Invaio pursues an enterprise B2B go-to-market that targets global agribusinesses and supply-chain leaders rather than individual growers, with named partners including Fundecitrus, Louis Dreyfus Company, and The Coca-Cola Company ("Save the Orange" initiative). Revenue mechanics are not publicly disclosed, but the model blends negotiated multi-year contracts routed through regional specialist sales teams with strategic co-development partnerships, future manufacturing collaborations (most notably with Ginkgo Bioworks for fermentation scale-up, announced February 2026), and downstream licensing potential. The company has raised over $142 million since inception — including an $88.9 million Series C led by Flagship Pioneering in May 2021 and $50 million in debt financing from K2 HealthVentures in October 2021 — and currently employs around 90 people of 22 nationalities.

The business is led by CEO and Board Director Amy O'Shea (appointed April 2024), with a leadership team that includes President/CCO Peleg Chevion, CCO Chris Judd, CFO Scott Kantor, and CSO Magalie Guilhabert, supported by a Scientific Advisory Board chaired by HHMI/NAS investigator Steve Jacobsen and including Nobel laureate Randy Schekman. Board representation spans PepsiCo (Pietro Tataranni), Ginkgo Bioworks (Ena Cratsenburg), and Novartis AI (Iya Khalil), providing direct cross-sector leverage into nutrition, synthetic biology, and AI/ML commercialization channels that complement the company's enterprise distribution strategy.

Invaio Sciences firmographics

Firmographics
Name
Invaio Sciences
Legal name
Invaio Sciences, Inc.
Website
https://invaio.com
Company type
Private
Founded year
2018
Operating status
Operating
Headcount range
51–100 employees
Short description
Invaio Sciences is an agricultural biotechnology company that uses an AI-driven peptide discovery engine and proprietary delivery platforms (Trecise™, MDPs, NLPs) to develop nature-positive crop protection solutions for citrus, vegetable, and row crop growers, sold via enterprise partnerships with global agribusinesses and supply-chain leaders.
Ownership category
akta.pro rank

Invaio Sciences industry classification

Industry
Product category
Agricultural biotechnology — biological crop protection
NAICS
Pesticide, Fertilizer, and Other Agricultural Chemical Manufacturing (3253), Pesticide and Other Agricultural Chemical Manufacturing (32532), Pesticide and Other Agricultural Chemical Manufacturing (325320)
SIC
Agricultural Chemicals (2870), Biological Products, (No Disgnostic Substances) (2836)
akta.pro industry
PRIMARYAFABAEAN
Biologicals Distribution & Field Application Services
Agriculture & Food Production/Agricultural Inputs & Agrochemicals/Biologicals & Biopesticides (Microbials, Botanicals, Beneficial Insects)
SECONDARYAFABAEAL
Biological Seed Treatments & Inoculants (within Biologicals)
Agriculture & Food Production/Agricultural Inputs & Agrochemicals/Biologicals & Biopesticides (Microbials, Botanicals, Beneficial Insects)
SECONDARYAFABAKAL
Organic Adjuvants & Spray Aids (OMRI Surfactants, Stickers, Oils)
Agriculture & Food Production/Agricultural Inputs & Agrochemicals/Organic & Regenerative Inputs (OMRI Inputs, Compost, Natural Pest Control)

Keywords

  • Biological crop protection
  • Agricultural biotechnology
  • Peptide discovery
  • Precision delivery
  • Sustainable agriculture

Where Invaio Sciences is headquartered

Location

Headquarters

HQ city
Cambridge
HQ country
United States
HQ region
North America

Offices7 records

Markets served

Invaio Sciences business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Personnel, Technology or R&D, Operations, Marketing or Sales, Supply Chain, Infrastructure

Revenue model

  1. Commercial product sales (pre-launch / transition phase): Series C press release (May 25, 2021) explicitly states Invaio is using funds 'to expand its sustainable agriculture technology platforms' and 'transition from R&D to a fully commercial enterprise focused on eco-friendly farming methods,' indicating product sales to growers and agribusiness customers are the intended primary revenue model as Invaio Citrus Health™ and Trecise™-based products launch. No specific pricing or revenue figures are disclosed.
  2. Strategic co-development and partnership-derived revenue: Revenue is also generated via strategic partnerships where Invaio supplies its Trecise™ / Biologicals by Design™ platforms to partners (e.g., Fundecitrus, Louis Dreyfus, The Coca-Cola Company, Ginkgo Bioworks) for joint development of HLB and crop protection solutions; the company describes preparing 'to launch our first HLB solution in Brazil.'
  3. Future licensing / manufacturing collaboration (with Ginkgo Bioworks): The February 2026 collaboration with Ginkgo Bioworks covers microbial strain engineering and fermentation scale-up for Invaio's peptide-based crop protection inputs, positioning Invaio for grower-friendly commercial-scale production and downstream licensing/royalty potential.

Pricing tiers

ModelBillingPrice
OtherMulti-year contractQuote-based B2B enterprise pricing — not publicly disclosed

Go-to-market motion4 records

Distribution channels4 records

Marketing channels9 records

Invaio Sciences product offering

Product offering

Core offering

Invaio Sciences develops and sells biological crop-protection solutions built on an AI-driven antimicrobial peptide discovery engine (Biologicals by Design™) paired with proprietary precision delivery platforms (Trecise™ tree infusion, Microbe-Derived Particles and Nature-derived Lipid nanoParticles). Its packaged solution lines target citrus greening (HLB) via Invaio Citrus Health™, vegetable pests and row-crop insects, and are sold primarily through enterprise partnerships with global agribusinesses and supply-chain leaders rather than direct-to-grower retail.

Product overview

Invaio Sciences offers a platform-plus-modules architecture for nature-positive agriculture. The core engine is the Biologicals by Design™ AI-driven peptide discovery platform, which is paired with three proprietary delivery platforms — Trecise™ (precision tree infusion), Nature-derived Lipid nanoParticles (NLPs), and Microbe-Derived Particles (MDPs) — that protect and deliver bioactives into crops. These platforms are packaged into solution lines targeting Tree Health (including Invaio Citrus Health™ for HLB/citrus greening), Vegetable Health, and Row Crop Health, with the Peptyde Bio antimicrobial peptide portfolio integrated after the December 2023 acquisition to bolster the fungicide and broader peptide pipeline.

Differentiator

Problem solved

Functional benefit

Brands

  • Biologicals by Design™: Proprietary AI- and machine-learning-powered discovery platform for designing nature-informed peptides for crop protection.
  • Trecise™
  • Invaio Citrus Health™

Products and services

  • Invaio Citrus Health™ Invaio's first citrus-focused solution targeting Huanglongbing (HLB/citrus greening); combines Trecise™ precision tree-infusion delivery with peptide-based bioactives and is suitable for use even on young trees. Targeted at Florida and Brazilian citrus growers.
  • Tree Health Solutions Solution line covering perennial crop trees (including citrus and other tree crops) using Trecise™ delivery to protect tree health from pests and disease while reducing pesticide, water and nutrient inputs.
  • Vegetable Health Solutions Targeted bioactives and delivery systems aimed at controlling pests in vegetable crops, including MDP-encapsulated peptides and proteins targeting diamondback moth and other resistant insect pests; demonstrated 2–5× performance vs. commercial biological benchmark in cabbage, kale, broccoli and cauliflower trials.
  • Row Crop Health Solutions Approaches for row crops including corn rootworm control, leveraging peptide and RNA-based actives delivered via MDP and NLP platforms to address insecticide-resistant populations in corn and other row crops.
  • Biologicals by Design™ platform AI-driven peptide discovery and design platform that uses generative AI, deep machine learning, structure-guided design, and genome mining for antimicrobial peptides to generate programmable, nature-derived active ingredients targeting specific pests and diseases with novel modes of action. Reported as 10x more efficient than traditional chemical discovery methods at identifying novel crop-health solutions. Sold/licensed to enterprise partners as part of co-development engagements.
  • Trecise™ precision infusion delivery system Proprietary precision infusion/tree-injection delivery technology that places active ingredients directly into the vascular system of trees, dramatically reducing chemical spray needs. Deployed commercially as the delivery backbone for Invaio Citrus Health™ against HLB and described as the first major innovation around targeted delivery in crop protection in 25 years.
  • Peptyde Bio antimicrobial peptide platform (acquired pipeline) Antimicrobial peptide discovery, design and characterization platform acquired by Invaio from Peptyde Bio in December 2023. Brings peptide candidates that complement or replace traditional chemical fungicides and integrates with Invaio's Biologicals by Design™ platform; focused initially on defensin-class AMPs for Botrytis cinerea, Fusarium spp., Septoria blotch, Asian soybean rust and certain oomycetes.

Quantifiable outcome

  • Biologicals by Design™ platform is 10x more efficient than traditional chemical discovery methods at identifying novel crop health solutions
  • +3 more outcomes

Companies that use Invaio Sciences

Customer profile

Named customers4 records

Segments4 records

Ideal customer profiles3 records

Invaio Sciences technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

AI capability8 records

Feature6 records

Invaio Sciences partnerships and signals

Strategic signal

Partnerships

Eleven partnerships are on record, tiered flagship, core and minor.

  • Ginkgo BioworksflagshipTechnology or Integration · 18 February 2026Collaboration announced February 18, 2026, in which Ginkgo Bioworks and Invaio Sciences will develop manufacturing technology for peptide-based crop protection products. Ginkgo will leverage its engineered microbial strains and fermentation processes to help Invaio scale production of peptides at grower-friendly costs, addressing increasing pest resistance to conventional agricultural chemistry.
  • FundecitrusflagshipStrategic or Co-development Partner · 13 January 2026Strategic collaboration announced January 13, 2025 (press release dated Jan 13, 2026) between Invaio Sciences and Fundecitrus (Fund for Citrus Protection, Araraquara, Brazil) to accelerate evaluation of peptide-based biological solutions against citrus greening (HLB). Fundecitrus provides specialized assays and field-based methods because CLas cannot be cultured in vitro; Invaio deploys its Trecise™ precision delivery platform to test candidates directly into citrus trees. Quotes from Ricardo Miranda (VP, Head of Global Development) and Avram Slovic (Head of LatAm).
  • The Coca-Cola CompanyflagshipGTM or Marketing Partner · 5 September 2025Press release dated September 5, 2025: 'Invaio Sciences Joins Forces with The Coca-Cola Company to Save the Orange.' Invaio participates in the Save the Orange initiative with Coca-Cola and Fundecitrus, supporting the citrus supply chain's adoption of biological HLB solutions and bringing nature-positive crop protection to global beverage supply.
  • Louis Dreyfus CompanycoreStrategic or Co-development Partner · 29 January 2024Press release dated January 29, 2024: 'Invaio Sciences and Louis Dreyfus Company Collaborate on Sustainable Citrus Groves for the Future.' The collaboration brings together Invaio's biological technologies and Louis Dreyfus' position as a major player in the global citrus supply chain to advance sustainable citrus production.
  • Peptyde BioflagshipStrategic or Co-development Partner · 7 December 2023On December 7, 2023, Invaio Sciences acquired Peptyde Bio, a company specializing in antimicrobial peptide technology for agriculture. The acquisition integrates Peptyde's portfolio of peptide candidates (defensins targeting Botrytis cinerea, Fusarium spp., Septoria blotch, Asian soybean rust, certain oomycetes) into Invaio's AI-driven Biologicals by Design™ discovery platform, accelerating sustainable crop protection solutions. The deal is believed to be the first exit for a Danforth Technology Company.
  • UCLA (Dr. Steve Jacobsen) — Scientific Advisory BoardflagshipOthers · 3 February 2021Dr. Steve Jacobsen, Professor of Molecular Cell and Developmental Biology and Biological Chemistry at UCLA and Howard Hughes Medical Institute Investigator (elected to NAS in 2011), chairs Invaio's Scientific Advisory Board. He contributed to building the SAB and recruiting R&D talent, and is also a scientific co-founder of Inari Agriculture (a Flagship Pioneering company).
  • UC Berkeley (Dr. Randy Schekman) — Scientific Advisory BoardcoreOthers · 3 February 2021Dr. Randy Schekman, Professor in the Department of Molecular and Cell Biology at the University of California, Berkeley, and HHMI investigator, joined the Invaio SAB. Schekman received the 2013 Nobel Prize in Medicine or Physiology for vesicle trafficking and joined to develop insights into harnessing vesicles to deliver biological molecules to plants.
  • NC State University (Dr. Rodolphe Barrangou) — Scientific Advisory BoardcoreOthers · 3 February 2021Dr. Rodolphe Barrangou, Distinguished Professor at NC State University (NAS, NAE, NAI and American Academy of Microbiology), joined the Invaio SAB. He brings experience commercializing CRISPR-related technologies and phage-host interaction science.
  • PepsiCo (Dr. Pietro Antonio Tataranni)minorStrategic or Co-development Partner · 18 November 2020On November 18, 2020, Invaio announced the appointment of Dr. Pietro Antonio Tataranni (Chief Medical Officer and Senior VP, R&D Life Sciences at PepsiCo) to its Board of Directors to contribute nutrition and bio-sciences expertise to Invaio's mission. PepsiCo itself is a board-affiliation partner rather than an operating commercial partner.
  • Ginkgo Bioworks (Ena Cratsenburg)minorStrategic or Co-development Partner · 18 November 2020Ena Cratsenburg, Chief Business Officer at Ginkgo Bioworks, joined Invaio's Board of Directors on November 18, 2020. This board relationship predated and supported the Feb 2026 manufacturing collaboration; Cratsenburg brings synthetic-biology and commercialization expertise.
  • Novartis AI Innovation Center (Dr. Iya Khalil)minorStrategic or Co-development Partner · 18 November 2020Dr. Iya Khalil, Global Head of the AI Innovation Center at Novartis (Novartis-Microsoft collaboration), joined Invaio's Board of Directors on November 18, 2020. Khalil is a co-founder of GNS Healthcare and brings AI / machine-learning expertise to support Invaio's discovery platforms.

Scale indicators12 records

Recent moves6 records

Expansion highlights6 records

Invaio Sciences competitors and assessment

Company assessment

Direct peers

  • Indigo Agriculture: Fellow Flagship Pioneering ag-biotech company developing microbial seed treatments and plant microbiome solutions. Directly comparable as a privately held, biology-based crop-inputs company backed by the same VC and pursuing nature-positive replacements for synthetic chemistries — Indigo also shares board overlap (Robert Berendes is Chairman of both Indigo and Invaio).
  • Inari Agriculture: Flagship Pioneering ag-biotech applying predictive design and multiplex gene editing to seeds; co-founded by Ignacio Martinez (Invaio's founding CEO) with Steve Jacobsen (Invaio SAB Chair) as scientific co-founder. Closest Flagship-sibling competitor in applying computational biology to plant/crop inputs.
  • AgBiome: Ag-biotech company using a proprietary microbial GENESIS™ discovery platform to identify biological crop-protection products (e.g., Howler and Theia fungicides). Closely comparable technology stack (biology discovery platform → commercial biocontrol products) targeting the same growers and same chemical-replacement thesis.
  • Pivot Bio: Microbial nitrogen-fixation company selling in-furrow and foliar biological products to row-crop growers as a replacement for synthetic nitrogen fertilizer. Same broad thesis (microbes replace synthetic chemistry), same customer type (large-scale growers), and similar scale-up-from-R&D-to-commercial trajectory.

Emerging players

  • BioConsortia: Ag-biotech developing microbial consortia products for nitrogen fixation, phosphorus solubilization, and biocontrol. Comparable discovery-then-product model and row-crop/specialty-crop overlap, though smaller and earlier-stage than Invaio.
  • Sound Agriculture: Ag-biotech offering microbe-based SOURCE™ nitrogen-fixation and EFFICIENCY™ bio-inspired chemistry products to row-crop growers. Comparable in offering nature-positive biological crop inputs that reduce synthetic fertilizer use; smaller scale and narrower product set than Invaio.

Others

  • Ginkgo Bioworks: Synthetic biology platform / cell-programming company that is also Invaio's manufacturing partner (Feb 2026 collaboration) and has a board representative (Ena Cratsenburg) on Invaio's board. Comparable in AI-driven biological design and biological manufacturing, but serves many end-markets beyond agriculture.

Broad incumbents

  • Syngenta (Syngenta Group): Global crop-protection incumbent (now part of Syngenta Group / Sinochem) offering chemical pesticides, seeds, and digital agronomy. Provides the synthetic chemistry baseline that Invaio's biologicals aim to replace; relevant as the dominant competitor Invaio must displace in growers' spray regimes.
  • Bayer Crop Science: Division of Bayer operating one of the world's largest crop-protection and seed franchises, with growing investment in biologics. Sets the competitive context for any nature-positive crop input alternative and is a benchmark for distribution scale.
  • Corteva Agriscience: Global crop-protection and seed major spun out of DowDuPont; offers chemical and biological inputs across row and specialty crops. Comparable broad incumbent that biologicals companies like Invaio must compete against on grower relationships and shelf-space.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights7 records

Customer concentration

Invaio Sciences social profiles

Digital presence

Invaio Sciences compliance and trust

Trust signal

Compliance3 records

Invaio Sciences financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Invaio Sciences leadership team

Management profile

Number of profiles

Profiles19 records

Invaio Sciences subsidiaries and ownership

Company hierarchy

Subsidiaries5 records

Invaio Sciences funding detail

Funding detail

Funding overview

Funding rounds4 records

Investors6 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Invaio Sciences M&A and investment

M&A and investment

M&A1 record

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Invaio Sciences

What does Invaio Sciences do?

Invaio Sciences develops and sells biological crop-protection solutions built on an AI-driven antimicrobial peptide discovery engine (Biologicals by Design™) paired with proprietary precision delivery platforms (Trecise™ tree infusion, Microbe-Derived Particles and Nature-derived Lipid nanoParticles). Its packaged solution lines target citrus greening (HLB) via Invaio Citrus Health™, vegetable pests and row-crop insects, and are sold primarily through enterprise partnerships with global agribusinesses and supply-chain leaders rather than direct-to-grower retail.

Is Invaio Sciences a public or private company?

Invaio Sciences is a private company. It is classified as venture growth investor backed and is currently operating.

When was Invaio Sciences founded?

Invaio Sciences was founded in 2018. It employs 51 to 100 people.

Where is Invaio Sciences based?

Invaio Sciences is headquartered in Cambridge, United States, in the North America region.

How does Invaio Sciences make money?

Three revenue lines are on record. Commercial product sales (pre-launch / transition phase) is the primary driver. The others are strategic co-development and partnership-derived revenue and future licensing / manufacturing collaboration (with Ginkgo Bioworks).

Who are Invaio Sciences's main competitors?

Direct peers on record are Indigo Agriculture, Inari Agriculture, AgBiome and Pivot Bio. Emerging players are BioConsortia and Sound Agriculture. Ginkgo Bioworks is listed as an others. Broad incumbents are Syngenta (Syngenta Group), Bayer Crop Science and Corteva Agriscience.

Does Invaio Sciences have an API?

No public API is recorded for Invaio Sciences.

What industry is Invaio Sciences in?

Invaio Sciences's product category is Agricultural biotechnology — biological crop protection. Its primary akta.pro industry code is AFABAEAN, Biologicals Distribution & Field Application Services, with a secondary code of AFABAEAL, Biological Seed Treatments & Inoculants (within Biologicals). Its NAICS code is 3253 and its SIC code is 2870.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
PR NewswireGinkgo Bioworks and Invaio Sciences Enter Collaboration to Develop Manufacturing Technology for Peptide-based Agricultural ProductsGinkgo Bioworks and Invaio Sciences announced a collaboration to develop strains that can efficiently manufacture peptide-based crop protection inputs for agricultural use. Under the agreement, Invaio will leverage Ginkgo's microbial platform and fermentation technology to scale production of its peptide-based crop protection solutions at grower-friendly costs. The collaboration aims to address increasing pest resistance to conventional chemistry by delivering next-generation biological alternatives.TipranksGinkgo Bioworks, Invaio Sciences enter collaborationGinkgo Bioworks and Invaio Sciences announced a collaboration to develop peptide-based crop protection inputs using microbial strain engineering and industrial-scale fermentation. Under the agreement, Invaio will leverage Ginkgo's platform and optimized microbial strains to manufacture its peptide-based products, with Ginkgo responsible for further optimizing strains and fermentation processes to meet Invaio's production goals. This partnership addresses growing grower demand for alternatives to conventional chemistry as pest resistance increases.Investing.comGinkgo Bioworks, Invaio Sciences partner on peptide crop protection By Investing.comGinkgo Bioworks and Invaio Sciences announced a collaboration to develop microbial strains for manufacturing peptide-based crop protection products at commercial scale, leveraging Ginkgo's platform and engineered microbial strains through industrial-scale fermentation. The partnership aims to address increasing pest resistance challenges in agriculture by creating biological alternatives to conventional pesticides. The collaboration is part of Ginkgo's broader strategy to support companies at various stages of scale-up and manufacturing, from strain engineering to bioprocess development.PR NewswireFlagship Appoints Amy O'Shea as CEO-Partner and Chief Executive Officer of Invaio SciencesFlagship Pioneering and Invaio Sciences announced the appointment of Amy O'Shea as CEO-Partner at Flagship Pioneering and as Chief Executive Officer and Board Director of Invaio Sciences, effective immediately. O'Shea brings over 20 years of leadership experience in agriculture, food, and pharmaceutical industries, most recently serving as President and CEO of Certis Biologicals, a division of Mitsui & Co. The appointment is positioned to drive Invaio's commercial expansion of its citrus greening solution and advance its biological agriculture technologies.PR NewswireInvaio Sciences and Louis Dreyfus Company Collaborate on Sustainable Citrus Groves for the FutureInvaio Sciences and Louis Dreyfus Company announced a three-year collaboration to combat citrus greening disease in Brazil. The partnership uses Invaio's Trecise technology to reduce chemical use by up to 90% and improve crop sustainability. The goal is to enhance water, input, and fuel management on LDC-managed farms.PR NewswireInvaio Sciences and Louis Dreyfus Company Collaborate on Sustainable Citrus Groves for the FutureInvaio Sciences and Louis Dreyfus Company announced a three-year collaboration to combat citrus greening disease in Brazil. The partnership uses Invaio's Trecise technology to reduce chemical use by up to 90% and improve crop health. The goal is to enhance sustainability and traceability on LDC-managed farms.FinSMEsInvaio Sciences Acquires Peptyde BioInvaio Sciences acquired Peptyde Bio, a Cambridge, MA-based company that discovers and designs novel peptides for agriculture. The deal amount was not disclosed. The acquisition adds an established platform and IP portfolio to accelerate peptide discovery for sustainable crop protection.PR NewswireInvaio Sciences acquires Peptyde Bio to accelerate nature-positive crop protection pipelineInvaio Sciences acquired Peptyde Bio, a company that discovers and designs novel peptides for agriculture. The acquisition adds Peptyde Bio's confirmed peptide lead candidates to Invaio's pipeline, aiming to accelerate sustainable crop protection with lower pesticide and water use.InvaioInvaio Sciences acquires Peptyde Bio to accelerate nature-positive crop protection pipelineInvaio Sciences has acquired Peptyde Bio to integrate its peptide discovery platform and IP portfolio into Invaio's AI-enabled crop protection pipeline. This strategic move aims to accelerate the development of nature-positive biological actives that reduce pesticide use while maintaining crop health. The acquisition marks the first exit for a company launched by the Danforth Technology Company.AgriBusiness GlobalInvaio Sciences Acquires Peptyde Bio to Accelerate Nature-Positive Crop Protection PipelineInvaio Sciences has acquired Peptyde Bio, a company specializing in the discovery and design of novel peptides for agricultural use, to accelerate its nature-positive crop protection pipeline. This acquisition integrates Peptyde Bio’s IP portfolio into Invaio’s AI-driven discovery engine and biological delivery systems to develop sustainable pest and disease control solutions. The deal marks the first exit for a startup incubated by the Danforth Technology Company.